πŸ•΅οΈ Entera BIO Ltd. ($ENTX)

SEC insider & ownership activity, last 12 months Β· CIK 1638097 Β· every row links its SEC filing

Over the last 12 months insiders bought $141K with no open-market selling against it. Geno J. Germano bought $56K in discretionary trades (Feb–Mar). No red-flag 8-Ks in the window.

Aug 2025: net +$0 Sep 2025: net +$0 Oct 2025: net +$0 Nov 2025: net +$0 Dec 2025: net +$20K Jan 2026: net +$0 Mar 2026: net +$38K Mar 2026: net +$38K Apr 2026: net +$0 May 2026: net +$0 Jun 2026: net +$0 Jul 2026: net +$0
Monthly net open-market insider flow, last 12 months (up = net buying)

Insider flow

5 buyers, $141K (8 lots) Β· 0 sellers, $0 (0 lots)

InsiderBuysBoughtSellsSoldLast
Geno J. Germano2$56K 0–Mar 9, 2026
Ellis Sean2$35K 0–Mar 5, 2026
Toledano Miranda Jayne1$20K 0–Dec 29, 2025
Steven D. Rubin2$19K 0–Feb 12, 2026
Taitel Haya1$11K 0–Feb 10, 2026

5%+ holders

HolderStakeClassScheduleEvent
OPKO Health, Inc. 8.1% 13GApr 2, 2025 filing β†—

Planned insider sales (Form 144)

No sale notices filed in the last 12 months.

Material events (8-K)

ItemEvent date
Material agreement (1.01)Jul 26, 2026 filing β†—
Unregistered equity sale (3.02)Jul 26, 2026 filing β†—
Officer/director changes (5.02)Jul 26, 2026 filing β†—
Financial Statements and Exhibits (9.01)Jul 26, 2026 filing β†—
Officer/director changes (5.02)Jul 14, 2026 filing β†—
Charter/bylaw changes (5.03)Jul 14, 2026 filing β†—
Shareholder vote (5.07)Jul 14, 2026 filing β†—
Financial Statements and Exhibits (9.01)Jul 14, 2026 filing β†—
Earnings (2.02)May 8, 2026 filing β†—
Reg FD disclosure (7.01)May 8, 2026 filing β†—
Financial Statements and Exhibits (9.01)May 8, 2026 filing β†—
Material agreement (1.01)Apr 1, 2026 filing β†—
Unregistered equity sale (3.02)Apr 1, 2026 filing β†—
Financial Statements and Exhibits (9.01)Apr 1, 2026 filing β†—
Earnings (2.02)Mar 27, 2026 filing β†—
Reg FD disclosure (7.01)Mar 27, 2026 filing β†—
Financial Statements and Exhibits (9.01)Mar 27, 2026 filing β†—
Reg FD disclosure (7.01)Mar 4, 2026 filing β†—
Financial Statements and Exhibits (9.01)Mar 4, 2026 filing β†—
Officer/director changes (5.02)Feb 4, 2026 filing β†—
Reg FD disclosure (7.01)Feb 4, 2026 filing β†—
Financial Statements and Exhibits (9.01)Feb 4, 2026 filing β†—
Material agreement (1.01)Jan 29, 2026 filing β†—
Officer/director changes (5.02)Jan 29, 2026 filing β†—
Reg FD disclosure (7.01)Jan 29, 2026 filing β†—
Financial Statements and Exhibits (9.01)Jan 29, 2026 filing β†—
Earnings (2.02)Nov 14, 2025 filing β†—
Reg FD disclosure (7.01)Nov 14, 2025 filing β†—
Financial Statements and Exhibits (9.01)Nov 14, 2025 filing β†—
Earnings (2.02)Aug 8, 2025 filing β†—